河北医科大学学报

• 论著 • 上一篇    下一篇

利拉鲁肽对2型糖尿病轻度认知功能损害患者认知功能、尿白蛋白与肌酐比值、足细胞标志蛋白的影响

  

  1. 河北医科大学第一医院内分泌科,河北 石家庄 050031
  • 出版日期:2019-02-25 发布日期:2019-01-16
  • 作者简介:刘璠(1980-),女,河北武邑人,河北医科大学第一医院副主任医师,医学硕士,从事内分泌与代谢疾病诊治研究。
  • 基金资助:
    河北省科技计划项目(16277789D);河北省医学科学研究重点课题(20170506)

The effects of liraglutide on cognitive function, Urine albumincreatinine ratio and podocalyxin in patients with type 2 diabetic mild cognitive impairment#br#

  1. Department of Endocrinology, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China
  • Online:2019-02-25 Published:2019-01-16

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗探讨利拉鲁肽对2型糖尿病轻度认知功能损害(mild cognitive impairment,MCI)患者蒙特利尔认知评估量表(Montreal Cognitive Assessment,MoCA)评分、尿白蛋白与肌酐比值(albumincreatinine ratio,ACR)、足细胞标志蛋白(podocyte proteins,PCX)的影响。
〖HTH〗方法〖HTSS〗〖KG*2〗将80例2型糖尿病MCI患者随机分为对照组(40例)和利拉鲁肽组(40例),对照组给予原治疗方案,利拉鲁肽组改用利拉鲁肽治疗,疗程均为24周。比较治疗前及治疗后24周时2组收缩压(systolic blood pressure,SBP)、舒张压(diastolic blood pressure,DBP)、糖化血红蛋白(hemoglobin A1c,HbA1c)、空腹血糖(fasting plasma glucose,FPG)、总胆固醇(total cholesterol,TC)、三酰甘油(triglycerides,TG)、尿ACR、PCX。应用MoCA评估患者认知功能。
〖HTH〗结果〖HTSS〗〖KG*2〗2组治疗前、治疗后和2组治疗前后FPG、HbA1c、SBP、DBP、TG、TC差异均无统计学意义(P>005)。治疗前,2组MoCA评分、尿ACR、PCX差异均无统计学意义(P>005);治疗后,对照组MoCA评分、尿ACR、PCX与治疗前差异均无统计学意义(P>005),利拉鲁肽组MoCA评分显著高于治疗前,尿ACR、PCX显著低于治疗前,利拉鲁肽组MoCA评分显著高于对照组(P<005),尿ACR、PCX显著低于对照组,差异均有统计学意义(P<005)。
〖HTH〗结论〖HTSS〗〖KG*2〗利拉鲁肽可改善2型糖尿病MCI患者认知功能,降低其尿ACR和PCX水平。

关键词: 糖尿病, 2型, 轻度认知障碍, 利拉鲁肽

Abstract: [Abstract]〓Objective〖HTSS〗〓To explore the effects of liraglutide on score of Montreal Cognitive Assessment(MoCA), urine albumincreatinine ratio(ACR) and urinary podocalyxin(PCX) in patients with type 2 diabetic mild cognitive impairment.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓 Eighty patients with type 2 diabetic mild cognitive impairment were collected and randomly divided into control group(n=40) and liraglutide group(n=40). Premixed insulin was administrated in control group for 24 weeks while liraglutide in liraglutide group. The systolic blood pressure(SBP), diastolic blood pressure(DBP), hemoglobin A1c(HbA1c), fasting plasma glucose(FPG), total cholesterol(TC), triglyceride(TG), urine ACR and urine PCX of were measured and compared before the treatment and 24 weeks after the treatment. Patients cognitive function was assessed by MoCA.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓There were no significant difference in FBG, HbA1c, SBP, DBP, TG, and TC between two groups before the treatment and 24 weeks after the treatment, while there was no significant change in FBG, HbA1c, SBP, DBP, TG, and TC after the treatment in the two groups(P>005). Before the treatment, there were no significant difference in the core of MoCA, urine ACR and PCX between two groups(P>0.05). After the treatment, there were no significant change in the core of MoCA, urine ACR and PCX as compared with that before treatment in control group(P>0.05), while the core of MoCA in liraglutide group were significantly higher(P<005) and urine ACR and PCX lower than that before treatment(P<005). At 24 weeks after the treatment, the core of MoCA in liraglutide group was significant higher (P<005)and urine ACR and PCX were significant lower than that of control group(P<005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Liraglutide maybe improve cognitive function and reduce urine ACR and PCX in patients with type 2 diabetic mild cognitive impairment.

Key words: diabetes mellitus, type 2, mild cognitive impairment, liraglutide